Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ) Following CEO Transition Plan Announcement
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $200 at TD Cowen
-
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
-
Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences
-
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
-
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
-
Jazz Pharmaceuticals (JAZZ) Expanded Access Program Suggests JZP-458 Launch is On Track - Cowen
-
Cowen's Conviction on Jazz Pharmaceuticals (JAZZ) 'Growing Stronger', Buy on Weakness
-
Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $190 at Cowen, Positive on GW Deal
-
Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
-
Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $200 at Cowen
-
Buy Jazz Pharmaceuticals (JAZZ) 'Aggressively' on Xyrem Headline Weakness - Cowen
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Cowen; 'Transitioning Growth Asset'
-
Cowen Reviews Eight Potential Strategic Options Allergen (AGN); PT Lowered to $255
-
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
-
Jazz Pharmaceuticals (JAZZ): KOLs Highlight Vyxeos Opportunity - Cowen
-
Jazz Pharmaceuticals' (JAZZ) JZP-110 Seen as $750M+ Product - Cowen
-
Jazz Pharmaceuticals (JAZZ): Upside Is Clear - Cowen
-
Jazz Pharmaceuticals (JAZZ): Xyrem Terms Are Very Favorable - Cowen
-
Cowen Reiterates Outperform Rating and $190 PT on Jazz Pharmaceuticals (JAZZ) Following Positive JZP-110 Data; 'A Complete Re-Rating is Nearing'
-
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
-
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
-
Teva (TEVA) Likely to Offer $90/Share for Mylan (MYL) in Next Step, Cowen Says
-
Notable Analyst Rating Changes 09/11: (BMY) (SYNC) (JAZZ) Upgraded; (SIRI) (TIBX) (GNOM) Downgraded
-
Cowen Upgrades Jazz Pharmaceuticals (JAZZ) to Outperform
-
Cowen Starts Jazz Pharmaceuticals (JAZZ) at Neutral
-
Notable Analyst Rating Changes 04/13: (JCI) (RRC) (DOV) Upgraded; (ITW) (CNX) (NOK) Downgraded

